Genmab A (GMAB) Income towards Parent Company (2018 - 2026)
Genmab A's (GMAB) quarterly Income towards Parent Company came in at $287.0 million in Q2 2026, down 64.26% on a YoY basis from $803.0 million in Q2 2025, and down 94.95% quarter-over-quarter from $5.7 billion in Q1 2026.
Analysis
Genmab A (GMAB) Income towards Parent Company (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has reported Income towards Parent Company for 9 consecutive years, with $287.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income towards Parent Company fell 64.26% year-over-year to $287.0 million; the trailing twelve-month figure through Jun 2026 stood at $12.5 billion (up 12.91% YoY), and the FY2025 full-year result was $963.0 million, down 81.25% from the prior year.
- Income towards Parent Company declined to $287.0 million in Q2 2026 per GMAB's latest filing, from $5.7 billion in the prior quarter.
- Across five years, Income towards Parent Company topped out at $5.8 billion in Q3 2025 and bottomed at -$2.5 billion in Q4 2023.
- Historically, Income towards Parent Company has averaged $2.2 billion across 5 years, with a median of $2.5 billion in 2022.
- The sharpest annual moves came in 2023 and 2025: Income towards Parent Company slumped 3568.93% in 2023, then soared 303.27% in 2025.
- Over 5 years, Income towards Parent Company stood at $73.2 million in 2022, then plunged by 3568.93% to -$2.5 billion in 2023, then soared by 288.86% to $4.8 billion in 2024, then grew by 19.99% to $5.8 billion in 2025, then tumbled by 95.01% to $287.0 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered $287.0 million, $5.7 billion, and $5.8 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 287.00 Mn |
| Mar 31, 2026 | 5.68 Bn |
| Sep 30, 2025 | 5.75 Bn |
| Jun 30, 2025 | 803.00 Mn |
| Mar 31, 2025 | 5.30 Bn |
| Sep 30, 2024 | 4.79 Bn |
| Jun 30, 2024 | 199.12 Mn |
| Mar 31, 2024 | 4.71 Bn |
| Dec 31, 2023 | -2.54 Bn |
| Sep 30, 2023 | 2.86 Bn |
| Jun 30, 2023 | 161.12 Mn |
| Mar 31, 2023 | 2.59 Bn |
| Dec 31, 2022 | 73.16 Mn |
| Sep 30, 2022 | 2.53 Bn |
| Jun 30, 2022 | 253.74 Mn |
| Dec 31, 2021 | -2.27 Bn |
| Sep 30, 2021 | 2.46 Bn |
| Jun 30, 2021 | 169.09 Mn |
| Mar 31, 2021 | 1.42 Bn |
| Dec 31, 2020 | 1.67 Bn |